Creavo has developed diagnostic technology using magnetocardiography (MCG) to measure fluctuations in magnetic fields caused by heart activity. The first product resulting from the work will help physicians in A&E departments rule out significant heart disease in patients presenting with chest pains. This represents a considerable portion of A&E patients but existing protocols take up to 12 hours to resolve the issue which causes stress to them, and also imposes significant costs on the NHS.
Location: United Kingdom, England, Coventry
Total raised: $17.35M
Investors 1
| Date | Name | Website |
| - | Parkwalk A... | parkwalkad... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.07.2017 | - | $17.35M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 03.07.2017 | Creavo Medical Technologies Ltd - Closes £13.4m ($17m) fundi... | Creavo Medical Technologies, the UK-based med-tech company, has announced that it has raised a fur... | ipgroupplc... |
| - | Creavo Medical Technologies – Parkwalk closes investment | We are pleased to announce that the Parkwalk Opportunities Fund has made an investment in Creavo Med... | parkwalkad... |
| - | Parkwalk H1 2017 update | It has been a busy first half of the year at Parkwalk. Our proprietary access to deal-flow has enabl... | parkwalkad... |
| - | EIS: more than financial returns | As institutional investors increasingly regard ESG as an important element of their investment decis... | parkwalkad... |